Dechra Pharmaceuticals PLC (DECP.L)

DECP.L on London Stock Exchange

23 Sep 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for DECP.L


Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The... (more)


Beta: 0.28
Market Cap(Mil.): £1,235.46
Shares Outstanding(Mil.): 92.75
Dividend: 12.91
Yield (%): --


  DECP.L Industry Sector
P/E (TTM): 93.62 36.61 36.60
EPS (TTM): 0.14 -- --
ROI: 3.38 14.46 13.91
ROE: 5.40 15.26 14.82

BRIEF-Dechra Pharmaceuticals gets FDA approval for first U.S. generic entrant antibiotic

* Dechra is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) for a generic antibiotic

09 Sep 2016

BRIEF-Dechra Pharmaceuticals full year revenue up 21.7 pct

* Fy revenue growth in our existing eu pharmaceuticals segment was 5.7pct (at cer)

05 Sep 2016

BRIEF-Consort Medical CFO resigns to join Dechra Pharma

* Says Richard Cotton, group chief financial officer will be leaving business after interim results in Dec. 2016

17 Aug 2016

BRIEF-Dechra Pharma poaches finance head from Consort Medical

* Appointment of Richard Cotton as chief financial officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

17 Aug 2016

BRIEF-Dechra names Tony Rice as chairman from October

* Tony rice has been appointed to board as non-executive director and will be appointed as chairman with effect from conclusion of company's annual general meeting on 21 october 2016 Source text for Eikon: Further company coverage: (Reporting By UK Bureau)

08 Apr 2016

Earnings vs. Estimates